Global Darbepoetin Alfa (Aranesp) Market Projected to Grow at 5% CAGR, Reaching $7.37 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Darbepoetin Alfa (Aranesp) Industry Market Size Be by 2025?
In recent years, there has been a consistent expansion of the darbepoetin alfa (aranesp) market. It's projected to increase from $5.81 billion in 2024 to $6.06 billion in 2025, boasting a compound annual growth rate (CAGR) of 4.2%. This growth throughout the historical period can be traced back to advancements in anemia treatments, increased demand for erythropoiesis-stimulating agents (ESAs), innovation in the biopharmaceutical sector, better clinical acceptance, and enhanced patient outcomes.

What's the Long-Term Growth Forecast for the Darbepoetin Alfa (Aranesp) Market Size Through 2029?
It is anticipated that the market size for darbepoetin alfa (aranesp) will experience substantial growth in the coming years, eventually reaching $7.37 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 5.0%. Factors contributing to this expansion in the forecast period include healthcare reimbursement policies, heightened awareness and education, development of healthcare infrastructure, the demand for renal care, and an aging population. Key trends expected during the forecast period encompass global market penetration, incorporation of digital health, personalized treatment methods, acceptance of biosimilars, and the use of long-acting formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/darbepoetin-alfa-aranesp-global-market-report

What Are the Key Growth Drivers Fueling the Darbepoetin Alfa (Aranesp) Market Expansion?
The surge in chronic illnesses is projected to fuel the darbepoetin alfa market's expansion. Chronic diseases, which can worsen over time, are illnesses that persist for three months or more. Darbepoetin alfa is employed to manage numerous chronic diseases and to counteract anemia caused by chemotherapy in cancer. For example, the Australian Institute of Health and Welfare, an Australian Government statutory authority, reported in June 2024 that chronic conditions accounted for 171,500 fatalities in 2022, or 90% of all deaths, at a rate of 659 per 100,000 individuals. The age-standardised death rate from chronic conditions dropped to 448 per 100,000 in 2020, but rose to 459 in 2021 and 490 in 2022. Therefore, the escalating prevalence of chronic illnesses is spurring the growth of the darbepoetin alfa market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp

What Are the Key Trends Driving Darbepoetin Alfa (Aranesp) Market Growth?
A key trend that is gaining traction in the darbepoetin alfa market is product innovation. Top players in the darbepoetin alfa market are incorporating new technologies to maintain their market standing. For example, in February 2023, UK-based pharmaceutical and biotech company GlaxoSmithKline. Ltd. introduced Jesduvroq (daprodustat) to the US Food and Drug Administration (FDA), a US government agency, for approval. Daprodustat, otherwise known as recombinant human erythropoietin (rhEPO, darbepoetin alfa, or epoetin alfa), is an oral inhibitor of hypoxia-inducible factor prolyl hydroxylase, utilized as a once-daily treatment for anemia caused by chronic kidney disease (CKD) in patients who have been on dialysis for a minimum of four months.

How Is the Darbepoetin Alfa (Aranesp) Market Segmented?
The darbepoetin alfa (aranesp) market covered in this report is segmented -

1) By Type: Epogen, Procrit, Aranesp, Other Types
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Patients With Chronic Kidney Disease, Patients With Cancer, Other Applications

Subsegments:
1) By Epogen: Standard Formulations, Enhanced Formulations
2) By Procrit: Standard Formulations, Biosimilars
3) By Aranesp: Single-Dose Vials, Multi-Dose Vials
4) By Other Types: Combination Therapies, Alternative Erythropoiesis-Stimulating Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12171&type=smp

Which Companies Are Leading the Charge in Darbepoetin Alfa (Aranesp) Market Innovation?
Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.

Which Regions Are Leading the Global Darbepoetin Alfa (Aranesp) Market in Revenue?
North America was the largest region in the darbepoetin alfa (Aranesp) market in 2024. The regions covered in the darbepoetin alfa (Aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12171

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.